BCRX logo

BioCryst Pharmaceuticals Inc. (BCRX)

$7.45

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BCRX

Market cap

$1.92B

EPS

-1.41

P/E ratio

--

Price to sales

2.32

Dividend yield

--

Beta

0.541406

Price on BCRX

Previous close

$7.61

Today's open

$7.63

Day's range

$7.41 - $7.74

52 week range

$6.23 - $11.22

Profile about BCRX

CEO

Jon P. Stonehouse

Employees

435

Headquarters

Durham, NC

Exchange

Nasdaq Global Select

Shares outstanding

257299269

Issue type

Common Stock

BCRX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BCRX

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —

news source

GlobeNewsWire • Nov 13, 2026

news preview

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.

news source

Zacks Investment Research • Nov 10, 2026

news preview

BioCryst Pharmaceuticals Q3 Earnings Call Highlights

BioCryst Pharmaceuticals NASDAQ: BCRX reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.

news source

MarketBeat • Nov 4, 2026

news preview

BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst

BioCryst Pharmaceuticals delivered Q3 2026 results ahead of expectations, maintaining 2026 guidance and highlighting Orladeyo's ongoing growth in a competitive HAE market. BCRX's valuation appears modest at ~3.5x forward P/S and ~11x forward P/E (excluding IPR&D), but future upside depends on pipeline execution, especially navenibart. Management pivots to external innovation, targeting >$1bn revenues by 2030 with Orladeyo, navenibart, and BCX17725, while royalty burdens are set to ease after 2029.

news source

Seeking Alpha • Nov 4, 2026

news preview

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Nick Wilder - Manager of Investor Relations Charles Gayer - CEO, President & Director Babar Ghias - CFO & Head of Corporate Development Sandeep Menon - Chief Research & Development Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Stacy Ku - TD Cowen, Research Division Jeremiah Lorentz - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the BioCryst Third Quarter 2026 Earnings Call.

news source

Seeking Alpha • Nov 4, 2026

news preview

BioCryst Reports Third Quarter 2026 Financial Results

— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 4, 2026

news preview

BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Oct 30, 2026

news preview

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16.

news source

GlobeNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BioCryst Pharmaceuticals Inc.

Open an M1 investment account to buy and sell BioCryst Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BCRX on M1